Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a German referral center

Annals of the New York Academy of Sciences

Volumn 1014, Issue , 2004, Pages 222-233

  Pape, Ulrich Frank ^a,b   Böhmig, Michael ^a   Berndt, Uta ^a   Tiling, Nikolaus ^a   Wiedenmann, Bertram ^a   Plöckinger, Ursula ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Carcinoid; Chemotherapy; Interferon alpha; Metastasis; Neuroendocrine tumor; Somatostatin analogue; Surgery; Survival

Indexed keywords

ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; GASTROINTESTINAL CARCINOMA; GERMANY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; ILEUM; JEJUNUM; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUROENDOCRINE TUMOR; PANCREAS; PANCREAS CARCINOMA; PUBLIC HEALTH SERVICE; STATISTICAL SIGNIFICANCE; SURGICAL PATIENT; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 2342495360     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1294.025     Document Type: Article

References (32)

1. NEWTON, J.N., A.J. SWERDLOW, S.S. DOS, et al. 1994. The epidemiology of carcinoid tumours in England and Scotland. Br. J. Cancer 70: 939-942.
2. JANSON, E.T., L. HOLMBERG, M. STRIDSBERG, et al. 1997. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann. Oncol. 8: 685-690.
3. LEVI F., V.C. TE, L. RANDIMBISON, et al. 2000. Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974-97. Br. J. Cancer 83: 952-955.
4. QUAEDVLIEG, P.F., O. VISSER, C.B. LAMERS, et al. 2001. Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann. Oncol. 12: 1295-1300.
5. MODLIN, I.M., K.D. LYE & M. KIDD. 2003. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97: 934-959.
6. Bartsch, D.K., T. Schilling, A. Ramaswamy, et al. 2000. Management of nonfunctioning islet cell carcinomas. World J. Surg. 24: 1418-1424.
7. CAPELLA, C., P.U. HEITZ, H. HOFLER, et al. 1995. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch. 425: 547-560.
8. WILLIAMS, E.D. & M. SANDLER. 1963. The classification of carcinoid tumors. Lancet 1: 238-239.
9. MOERTEL, C.G., M. LEFKOPOULO, S. LIPSITZ, et al. 1992. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N. Engl. J. Med 326: 519-523.
10. PLÖCKINGER, U. & B. WIEDENMANN. 2001. Systemic therapy for metastatic or residual extrapancreatic neuroendocrine tumors. In Surgical Endocrinology: A Clinical Syndromes Approach. G.M. Doherty & B. Skogseid, Eds. :461-476. Lippincott. Philadelphia.
11. ARNOLD, R., M.E. TRAUTMANN, W. CREUTZFELDT, et al. 1996. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 38: 430-438.
12. FAISS, S., U.F. PAPE, M. BOHMIG, et al. 2003. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group. J. Clin. Oncol. 21: 2689-2696.
13. RINDI, G., C. CAPELLA & E. SOLCIA. 1998. Cell biology, clinicopathological profile, and classification of gastro-enteropancreatic endocrine tumors. J. Mol. Med 76: 413-420.
14. REHFELD, J.F. 1998. The new biology of gastrointestinal hormones. Physiol. Rev. 78: 1087-1108.
15. ONAITIS, M.W., P.M. KIRSHBOM, T.Z. HAYWARD, et al. 2000. Gastrointestinal carcinoids: characterization by site of origin and hormone production. Ann. Surg. 232: 549-556.
16. KIRSHBOM, P.M., A.R. KHERANI, M.W. ONAITIS, et al. 1999. Foregut carcinoids: a clinical and biochemical analysis. Surgery 126: 1105-1110.
17. KIRSHBOM, P.M., A.R. KHERANI, M.W. ONAITIS, et al. 1998. Carcinoids of unknown origin: comparative analysis with foregut, midgut, and hindgut carcinoids. Surgery 124: 1063-1070.
18. SHEBANI, K.O., W.W. SOUBA, D.M. FINKELSTEIN, et al. 1999. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann. Surg. 229: 815-821.
19. SOLCIA, E., G. KLÖPPEL & L.H. SOBIN. 2000. WHO International histological classification of tumours: histological typing of endocrine tumours. Springer. New York.
20. WIEDENMANN, B., R.T. JENSEN, M. MIGNON, et al. 1998. Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors: general recommendations by a consensus workshop. World J. Surg. 22: 309-318.
21. GRAMA, D., B. ERIKSSON, H. MARTENSSON, et al. 1992. Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes. World J. Surg. 16: 632-639.
22. HOCHWALD, S.N., S. ZEE, K.C. CONLON, et al. 2002. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J. Clin. Oncol. 20: 2633-2641
23. SPRENGER, A., M WIED & H.H. MUELLER. 2001. Prognostic factors in patients with neuroendocrine gastroenteropancreatic (GEP) tumors [abstr]. Gastroenterology 120: 2743.
24. HELLMAN, P., T. LUNDSTROM, U. OHRVALL, et al. 2002. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J. Surg. 26: 991-997.
25. SCHINDL, M., K. KACZIREK, C. PASSLER, et al. 2002. Treatment of small intestinal neuroendocrine tumors: is an extended multimodal approach justified? World J. Surg. 26: 976-984.
26. LO, C.Y., J.A. VAN HEERDEN, G.B. THOMPSON, et al. 1996. Islet cell carcinoma of the pancreas. World J. Surg. 20: 878-883.
27. PELLEY, R.J. & R.M. BUKOWSKI. 1999. Recent advances in systemic therapy for gastrointestinal neuroendocrine tumors. Curr. Opin. Oncol. 11: 32-37.
28. FAISS, S., U. RATH, U. MANSMANN, et al. 1999. Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion 60: 469-476.
29. FRANK, M., K.J. KLOSE, M. WIED, et al. 1999. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am. J. Gastroenterol. 94: 1381-1387.
30. DUCREUX, M., P. RUSZNIEWSKI, J.A. CHAYVIALLE, et al. 2000. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am. J. Gastroenterol. 95: 3276-3281.
31. KOLBY, L., G. PERSSON, S. FRANZEN & B. AHREN. 2003. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br. J. Surg. 90: 687-693.
32. PAPE, U.F. & B. WIEDENMANN. 2003. Adding interferon-alpha to octreotide slows tumour progression compared with octreotide alone but evidence is lacking for improved survival in people with disseminated midgut carcinoid tumours. Cancer Treat Rev. 29: 565-569.